The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial
This study has been completed.
Sponsor:
Cook
Information provided by:
Cook
ClinicalTrials.gov Identifier:
NCT00196079
First received: September 12, 2005
Last updated: January 30, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The ASPECT study is an Asian multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Cook Incorporated Paclitaxel Eluting Supra G Coronary Stent to reduce restenosis in the coronary artery.
Condition | Intervention |
---|---|
Coronary Artery Disease |
Device: Coronary stent |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Official Title: | The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial |
Resource links provided by NLM:
MedlinePlus related topics:
Coronary Artery Disease
Drug Information available for:
Paclitaxel
U.S. FDA Resources
Further study details as provided by Cook:
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery.
- Patient must be an acceptable candidate for coronary artery bypass surgery.
- Patient must have given signed informed consent.
- Patient agrees to return at one month for an office visit to assess cardiovascular status and at 4-6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram.
Exclusion Criteria:
- Patient is less than 18 years old.
- Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- The patient is simultaneously participating in another investigative interventional cardiovascular device or drug study.
- Patient has known hypersensitivity or contraindication to aspirin, Clopidogrel, or stainless steel, or a sensitivity to contrast dye that.
- Patient is pregnant.
- Patient has other medical condition that may cause the patient to be non-compliant with the protocol, confound the results or is associated with limited life expectancy.
Contacts and Locations
More Information
No publications provided
Keywords provided by Cook:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | April Lavender, RAC, Vice President for Regulatory Affairs, Cook |
ClinicalTrials.gov Identifier: | NCT00196079 History of Changes |
Other Study ID Numbers: | 506 |
Study First Received: | September 12, 2005 |
Last Updated: | January 30, 2012 |
Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Cook:
coronary artery stenosis drug eluting stent stent |
Additional relevant MeSH terms:
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Paclitaxel |
Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 16, 2012